Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-111113-052488a8",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "mini-max",
  "action": "support",
  "content": "\n\n# Practical Feasibility Assessment: TYROBP-SYK Hypotheses\n\n## Hypothesis 1: Downstream Effector Specificity (Revised confidence: 0.52)\n\n### Druggability: MODERATE\n| Component | Status | Notes |\n|-----------|--------|-------|\n| PI3K p110δ | High | Multiple inhibitors approved (idelalisib, duvelisib) |\n| CARD9 | Low | No selective inhibitors; challenging target |\n| Selective branching | Very Low | No tool compounds exist to test this premise |\n\n**Core Problem:** The hypothesis requires *simultaneously* enhancing PI3K-Akt while sparing/blocking CARD9. Current pharmacology cannot achieve this selectivity at the pathway level. We'd need bifunctional molecules or downstream effector modulators that don't exist.\n\n### Existing Compounds\n- PI3K inhibitors: FDA-approved for hematologic malignancies; significant toxicity (immune-related adverse events)\n- CARD9 inhibitors: None in pipeline\n- SYK inhibitors: Fostamatinib (approved for ITP), but can't selectively modulate branches\n\n### Development Cost & Timeline\n- **Cost:** $200-400M (de novo compound development)\n- **Timeline:** 10-15 years (novel mechanism, no established regulatory pathway)\n- **Risk:** High probability of failure in Phase II given pathway complexity\n\n### Safety Concerns\n- **PI3K inhibition:** colitis, hepatotoxicity, myelosuppression—poor CNS penetration anyway\n- **Systemic immune suppression:** Even if we wanted PI3K enhancement, peripheral toxicity is severe\n- **On-target effects:** Both pathways are ubiquitous; selectivity is the central unsolved problem\n\n### Verdict: **Low near-term feasibility.** Requires fundamental tool compound development. Recommend testing with available tools (PI3Kδ conditional knock-in models) before committing resources.\n\n---\n\n## Hypothesis 2: Disease Stage-Dependent Dual Role (Confidence: 0.68)\n\n### Druggability: MODERATE-HIGH\n| Component | Status | Notes |\n|-----------|--------|-------|\n| TREM2 agonist | High | Multiple candidates in development |\n| TYROBP signaling | Moderate | Downstream of TREM2, less directable |\n| Stage determination | Operational gap | No validated biomarker exists |\n\n**Core advantage:** TREM2 agonism is the most advanced therapeutic approach for this axis. AL002 (ALX Oncology), JNJ-77342102 ( Janssen), and others are in Phase I/II for Alzheimer's.\n\n### Existing Compounds & Trials\n| Compound | Company | Stage | Mechanism |\n|----------|---------|-------|-----------|\n| AL002 | ALX Oncology | Phase II (Alzheimer's) | TREM2 agonist |\n| JNJ-77342102 | Janssen | Phase I | TREM2 agonist |\n| Tiligemastat | Alector | Phase II | TREM2 agonist |\n| HOff233 | Hoffmann-La Roche | Phase I | TREM2 agonism |\n\n### Development Cost & Timeline\n- **Cost:** $150-300M (if leveraging existing programs)\n- **Timeline:** 5-8 years (existing platforms)\n- **Risk:** Moderate—TREM2 agonism has shown safety but unclear efficacy signal\n\n### Safety Concerns\n- **Cytokine dysregulation:** TREM2 modulation affects immune cell survival and activation\n- **Infection risk:** TREM2 affects macrophage function; theoretical susceptibility to intracellular pathogens\n- **Timing toxicity:** Enhanced signaling early may accelerate neurodegeneration if staging is miscalibrated\n\n### Verdict: **Highest feasibility.** This hypothesis is testable within current clinical programs. The critical experiment is biomarker stratification (CSF TREM2, PET-microglial activation) to identify early vs. late patients and correlate with treatment response.\n\n---\n\n## Hypothesis 3: Cell-Type Specific Effects (Confidence: 0.61)\n\n### Druggability: VERY LOW\n| Component | Status | Notes |\n|-----------|--------|-------|\n| Microglia-selective delivery | Unresolved | No validated strategy |\n| SYK cell-type targeting | Not feasible | SYK inhibitors cannot distinguish cell origin |\n| BBB penetration | Competing need | Must penetrate CNS but not affect peripheral |\n\n**Core Problem:** The therapeutic paradox requires delivering opposing effects to microglia vs. monocytes. No existing delivery technology can achieve this without cell-type-specific promoters or targeting ligands.\n\n### Existing Compounds\n- Fostamatinib: Penetrates BBB but hits both microglial and peripheral SYK\n- No selective microglial SYK modulators exist\n\n### Development Cost & Timeline\n- **Cost:** $500M+ (requires platform development)\n- **Timeline:** 15+ years\n- **Risk:** Extremely high\n\n### Safety Concerns\n- **Dual targeting:** Cannot separate beneficial microglial from harmful peripheral effects with current tools\n- **Off-target peripheral toxicity:** Systemic SYK inhibition affects platelets (SYK-dependent ITP pathway), causing bleeding risk\n\n### Verdict: **Not currently feasible.** Worth pursuing as a platform technology (microglia-specific delivery vehicles) but not viable as an immediate therapeutic strategy.\n\n---\n\n## Hypothesis 4: TREM2-Independent TYROBP Signaling (Confidence: 0.58)\n\n### Druggability: LOW\n| Component | Status | Notes |\n|-----------|--------|-------|\n| TREM2-independent interactors | Poorly characterized | PILRy, TREM2R, others undefined |\n| Selective pathway inhibition | Not possible | No tool compounds exist |\n| Target identification | Research gap | Requires systematic interactome mapping |\n\n**Core Problem:** We don't know enough. The TREM2-independent TYROBP interactome is insufficiently characterized in human microglia to",
  "tokens_used": "1338"
}